Physician profile
Thomas S Lee
NPI 1174588628
$2,695.31
in general payments reported to CMS, 2019-2025
26 companies · $363 in 2025
The $363 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $843 · 2020: $540 · 2021: $47.33 · 2022: $73.39 · 2023: $305 · 2024: $524 · 2025: $363.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,192.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,192.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $606.17 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $488.14 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $255.89 | 2019-2024 | |
| Amgen INC. | $153.78 | 2019-2025 | Evenity, Prolia |
| Merck Sharp & Dohme LLC | $153.48 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $122.36 | 2023-2025 | Eliquis |
| Sanofi-Aventis U.S. LLC | $87.98 | 2019-2020 | |
| Exact Sciences Corporation | $84.61 | 2023-2024 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $83.16 | 2019-2025 | Xifaxan |
| Lilly USA, LLC | $77.22 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $64.11 | 2019 | |
| Glaxosmithkline, LLC. | $63.76 | 2019-2020 | |
| Dexcom, INC. | $60.10 | 2024 | Dexcom G6 Transmitter |
| Mylan Specialty L.P. | $56.51 | 2020 | |
| Abbott Laboratories | $52.76 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $51.20 | 2025 | |
| Dermira, INC. | $44.68 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $36.35 | 2021-2024 | |
| Corcept Therapeutics | $29.44 | 2025 | Korlym |
| Sumitomo Pharma America, INC. | $23.42 | 2025 | Gemtesa |
| Boston Scientific Corporation | $19.90 | 2025 | Bulkamid - Bulkamid Urethral Bulking Pack 2ml (Ous) |
| Inspire Medical Systems, INC. | $19.09 | 2025 | Inspire |
| Halozyme INC | $18.06 | 2023 | |
| Sanofi Pasteur INC. | $15.85 | 2019 | |
| Azurity Pharmaceuticals, INC. | $14.79 | 2025 | |
| Amarin Pharma, INC. | $12.50 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.